Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

The role of lineage plasticity in prostate cancer therapy resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Jul 30. pii: clincanres.1423.2019. doi: 10.1158/1078-0432.CCR-19-1423. [Epub ahead of print]

PMID:
31363002
2.

Cancer and the Circadian Clock.

Shafi AA, Knudsen KE.

Cancer Res. 2019 Aug 1;79(15):3806-3814. doi: 10.1158/0008-5472.CAN-19-0566. Epub 2019 Jul 12. Review.

PMID:
31300477
3.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-2207. [Epub ahead of print]

PMID:
31266833
4.

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-2387. [Epub ahead of print]

PMID:
31266829
5.

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY.

Clin Cancer Res. 2019 Jul 15;25(14):4290-4299. doi: 10.1158/1078-0432.CCR-19-0404. Epub 2019 Apr 22.

PMID:
31010837
6.

Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset.

Knudsen KE, Feng FY.

Eur Urol. 2019 Sep;76(3):338-339. doi: 10.1016/j.eururo.2019.03.005. Epub 2019 Mar 15. No abstract available.

PMID:
30885533
7.

Counterpoint-Prostate Cancer Genomic Analysis: Routine or Research Only?

Kelly WK, Knudsen KE.

Oncology (Williston Park). 2018 Dec 17;32(12):607, 630-2. No abstract available.

8.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

PMID:
30467556
9.

PARP-1 regulates DNA repair factor availability.

Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE.

EMBO Mol Med. 2018 Dec;10(12). pii: e8816. doi: 10.15252/emmm.201708816.

10.

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.

Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.

Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.

PMID:
30450585
11.

Obesity Development in a Miniature Yucatan Pig Model: A Multi-compartmental Metabolomics Study on Cloned and Normal Pigs Fed Restricted or Ad Libitum High-Energy Diets.

Curtasu MV, Knudsen KEB, Callesen H, Purup S, Stagsted J, Hedemann MS.

J Proteome Res. 2019 Jan 4;18(1):30-47. doi: 10.1021/acs.jproteome.8b00264. Epub 2018 Oct 26.

PMID:
30365323
12.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

13.

Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.

Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298-E9307. doi: 10.1073/pnas.1807704115. Epub 2018 Sep 17.

14.

Prediagnosis plasma concentrations of enterolactone and survival after colorectal cancer: the Danish Diet, Cancer and Health cohort.

Kyrø C, Frederiksen K, Holm M, Nørskov NP, Knudsen KEB, Overvad K, Tjønneland A, Olsen A.

Br J Nutr. 2018 Sep 3:1-12. doi: 10.1017/S0007114518002143. [Epub ahead of print]

PMID:
30173678
15.

A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.

16.

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J.

Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9.

17.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

18.

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.

de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard ES, Hardiman G, Hussain MH, Diehl JA, Drake JM, Kelly WK, Knudsen KE.

Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8.

PMID:
29739788
19.

Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.

Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB.

Mol Pharm. 2018 May 7;15(5):1778-1790. doi: 10.1021/acs.molpharmaceut.7b01024. Epub 2018 Apr 4.

20.

DNA Damage Response in Prostate Cancer.

Schiewer MJ, Knudsen KE.

Cold Spring Harb Perspect Med. 2019 Jan 2;9(1). pii: a030486. doi: 10.1101/cshperspect.a030486. Review.

PMID:
29530944
21.

Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.

Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, Birbe R, Salvino JM, Dicker AP, Knudsen KE, Den RB.

Clin Cancer Res. 2018 Mar 15;24(6):1402-1414. doi: 10.1158/1078-0432.CCR-17-2074. Epub 2018 Jan 8.

22.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20. Erratum in: J Clin Oncol. 2018 May 20;36(15):1541.

23.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

24.

Differential impact of RB status on E2F1 reprogramming in human cancer.

McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE.

J Clin Invest. 2018 Jan 2;128(1):341-358. doi: 10.1172/JCI93566. Epub 2017 Dec 4.

25.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE.

Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13.

26.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

27.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

28.

PARP Inhibitors in Prostate Cancer.

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.

Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2. Review.

PMID:
28540598
29.

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle.

Schiewer MJ, Knudsen KE.

Cancer Cell. 2017 Apr 10;31(4):471-473. doi: 10.1016/j.ccell.2017.03.012.

30.

The microbial fermentation characteristics depend on both carbohydrate source and heat processing: a model experiment with ileo-cannulated pigs.

Nielsen TS, Jørgensen H, Knudsen KEB, Lærke HN.

Int J Food Sci Nutr. 2017 Nov;68(7):811-820. doi: 10.1080/09637486.2017.1307947. Epub 2017 Apr 2.

PMID:
28367709
31.

Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.

Thomas JD, Longen CG, Oyer HM, Chen N, Maher CM, Salvino JM, Kania B, Anderson KN, Ostrander WF, Knudsen KE, Kim FJ.

Cancer Res. 2017 May 1;77(9):2439-2452. doi: 10.1158/0008-5472.CAN-16-1055. Epub 2017 Feb 24.

32.

RB Loss Promotes Prostate Cancer Metastasis.

Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB.

Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.

33.

Mice Fed a High-Fat Diet Supplemented with Resistant Starch Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria.

Kieffer DA, Piccolo BD, Marco ML, Kim EB, Goodson ML, Keenan MJ, Dunn TN, Knudsen KE, Martin RJ, Adams SH.

J Nutr. 2016 Dec;146(12):2476-2490. Epub 2016 Nov 2.

34.

Obese Mice Fed a Diet Supplemented with Enzyme-Treated Wheat Bran Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria.

Kieffer DA, Piccolo BD, Marco ML, Kim EB, Goodson ML, Keenan MJ, Dunn TN, Knudsen KE, Adams SH, Martin RJ.

J Nutr. 2016 Dec;146(12):2445-2460. Epub 2016 Oct 19.

35.

Glycaemic and insulinemic response to dietary carbohydrates in horses.

Brøkner C, Austbø D, Næsset JA, Blache D, Knudsen KE, Hansen HH, Tauson AH.

Acta Vet Scand. 2016 Oct 20;58(Suppl 1):69.

36.

There and Back Again: The Middle Earth of DNA Repair.

Knudsen KE.

Mol Cancer Res. 2016 Oct;14(10):895-897. No abstract available.

37.

Validated LC-MS/MS Method for the Quantification of Free and Bound Lignans in Cereal-Based Diets and Feces.

Nørskov NP, Knudsen KE.

J Agric Food Chem. 2016 Nov 9;64(44):8343-8351. Epub 2016 Oct 27.

PMID:
27740756
38.

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.

Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB.

Urol Case Rep. 2016 Oct 1;9:51-54. eCollection 2016 Nov.

39.

Cell cycle-coupled expansion of AR activity promotes cancer progression.

McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE.

Oncogene. 2017 Mar 23;36(12):1655-1668. doi: 10.1038/onc.2016.334. Epub 2016 Sep 26.

40.

Use of antibiotics is associated with lower enterolactone plasma concentration.

Bolvig AK, Kyrø C, Nørskov NP, Eriksen AK, Christensen J, Tjønneland A, Knudsen KE, Olsen A.

Mol Nutr Food Res. 2016 Dec;60(12):2712-2721. doi: 10.1002/mnfr.201600566. Epub 2016 Sep 12.

PMID:
27500753
41.

A search for synbiotics: effects of enzymatically modified arabinoxylan and Butyrivibrio fibrisolvens on short-chain fatty acids in the cecum content and plasma of rats.

Nielsen TS, Jensen BB, Purup S, Jackson S, Saarinen M, Lyra A, Sørensen JF, Theil PK, Knudsen KE.

Food Funct. 2016 Apr;7(4):1839-48. doi: 10.1039/c6fo00114a.

PMID:
26988895
42.

Linking DNA Damage and Hormone Signaling Pathways in Cancer.

Schiewer MJ, Knudsen KE.

Trends Endocrinol Metab. 2016 Apr;27(4):216-225. doi: 10.1016/j.tem.2016.02.004. Epub 2016 Mar 1. Review.

43.

High-Throughput LC-MS/MS Method for Direct Quantification of Glucuronidated, Sulfated, and Free Enterolactone in Human Plasma.

Nørskov NP, Kyrø C, Olsen A, Tjønneland A, Knudsen KE.

J Proteome Res. 2016 Mar 4;15(3):1051-8. doi: 10.1021/acs.jproteome.5b01117. Epub 2016 Feb 12.

PMID:
26809233
44.

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.

Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY.

JAMA Oncol. 2016 Apr;2(4):471-80. doi: 10.1001/jamaoncol.2015.4955.

45.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

46.

Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD.

Mol Cancer Res. 2015 Dec;13(12):1591-601. doi: 10.1158/1541-7786.MCR-14-0626. Epub 2015 Aug 13.

47.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

48.

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.

Feng FY, de Bono JS, Rubin MA, Knudsen KE.

Mol Cell. 2015 Jun 18;58(6):925-34. doi: 10.1016/j.molcel.2015.04.016.

49.

Targeted LC-MS/MS Method for the Quantitation of Plant Lignans and Enterolignans in Biofluids from Humans and Pigs.

Nørskov NP, Olsen A, Tjønneland A, Bolvig AK, Lærke HN, Knudsen KE.

J Agric Food Chem. 2015 Jul 15;63(27):6283-92. doi: 10.1021/acs.jafc.5b01275. Epub 2015 Jul 2.

PMID:
26077973
50.

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA.

Neoplasia. 2015 Apr;17(4):385-99. doi: 10.1016/j.neo.2015.03.004.

Supplemental Content

Loading ...
Support Center